For years, the Coronary Artery Calcium (CAC) score has been the gold standard for a quick, non-invasive look at heart disease risk. It’s a vital tool that has helped millions of patients understand if they have "hardening of the arteries." But while a calcium score tells us that plaque is present, it only tells part of the story. As medical technology evolves, we are moving beyond simply identifying the presence of calcium to a much more detailed understanding of heart disease. With the advent of AI-enabled coronary plaque analysis, such as cvi42 | Plaque , patients and physicians now have access to a deeper level of insight that was previously impossible to achieve through standard screening alone. What is AI-Enabled Coronary Plaque Analysis? While a traditional calcium score measures the amount of mineralized (hard) plaque in your coronary arteries, AI-enabled plaque analysis looks at the "soft" or non-calcified plaque as well.
The Clinical Challenge & the cvi42 Solution Executive Summary Cardiovascular disease remains the leading cause of global mortality, yet diagnostic workflows remain fragmented. Traditionally, clinicians have been forced to navigate disconnected systems to assess a patient’s heart: one for anatomy (CCTA), another for function (CMR/Strain), and a third for vascular inflammation (PCAT/Plaque). This "siloed" approach creates diagnostic friction, increases costs, and delays life-saving interventions.
Clinical and Financial Wins that Scale From Single Platform to Strategic Advantage Clinicians, department heads, and executives each win differently from consolidation. Circle’s cvi 42 turns integration into tangible impact across MR, CT, structural heart, and electrophysiology programs. Why Circle’s platform stands apart For clinicians: Market-leading MR and CT tools in one workspace, with AI-driven workflows for function, tissue, plaque, and procedural planning—faster, reproducible reads and intuitive tools for edge cases. For department heads: Consistent multimodality workflows, research-grade quantification, and data exports supporting registries and AI projects. For finance leaders: Shared investment across MR and CT service lines, volumealigned pricing, and new reimbursable procedures like AIenabled coronary plaque analysis.
The activation of Category I CPT code 75577 on January 1, 2026, has transformed the reimbursement landscape for AI-enabled coronary plaque analysis, such as Circle Cardiovascular Imaging's FDA-cleared cvi 42 . This FAQ addresses key questions on payers, coverage, coding, payments, opportunities, threats, and value-based care impacts to guide adoption in cardiovascular imaging practices that ultimately lead to commercial viability. For Circle Cardiovascular Imaging customers deploying cvi 42 for plaque analysis, the new CPT 75577 landscape means reliable revenue streams (~$900-1,000 per case) with expanded payer access, but it requires refined billing to navigate bundling and denials. Overall, it accelerates the ROI on cvi 42 by enabling onsite AI processing that captures professional and technical fees hospitals previously outsourced.
